Scarica l'app Stockscreener
39.97
1.04%
-0.42
Dopo l'orario di chiusura:
39.97
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$40.39
Aprire:
$39.74
Volume 24 ore:
4.64M
Relative Volume:
0.85
Capitalizzazione di mercato:
$46.62B
Reddito:
$17.53B
Utile/perdita netta:
$1.58B
Rapporto P/E:
29.70
EPS:
1.3457
Flusso di cassa netto:
$444.18M
1 W Prestazione:
-1.60%
1M Prestazione:
+2.80%
6M Prestazione:
+26.41%
1 anno Prestazione:
+102.07%
Intervallo 1D:
$39.46
$40.50
Intervallo di 1 settimana:
$39.10
$40.86
Portata 52W:
$19.23
$42.02
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile
Nome
Teva Pharmaceutical Industries Ltd Adr
Settore
Telefono
972 (3) 914-8213
Indirizzo
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Compare TEVA vs TAK, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.97 | 46.62B | 17.53B | 1.58B | 444.18M | 1.3457 |
TAK
Takeda Pharmaceutical Co Adr
|
20.15 | 64.37B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.00 | 43.98B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
77.80 | 32.15B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
586.48 | 25.15B | 3.17B | 1.29B | 1.01B | 27.09 |
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-01 | Iniziato | TD Cowen | Buy |
| 2026-09-23 | Iniziato | Oppenheimer | Outperform |
| 2026-09-09 | Iniziato | Leerink Partners | Outperform |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-12-05 | Iniziato | Scotiabank | Sector Outperform |
| 2025-06-06 | Iniziato | Goldman | Buy |
| 2025-05-28 | Iniziato | Truist | Buy |
| 2025-05-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-07-10 | Aggiornamento | Argus | Hold → Buy |
| 2024-03-08 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2024-02-12 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-01-23 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-01-03 | Aggiornamento | Piper Sandler | Underweight → Neutral |
| 2023-12-18 | Iniziato | HSBC Securities | Buy |
| 2023-11-27 | Aggiornamento | UBS | Neutral → Buy |
| 2023-07-06 | Aggiornamento | UBS | Sell → Neutral |
| 2023-05-25 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-05-18 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-01-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-11-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-11-04 | Downgrade | UBS | Neutral → Sell |
| 2022-10-21 | Ripresa | Jefferies | Buy |
| 2022-08-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-06-14 | Ripresa | UBS | Neutral |
| 2022-05-17 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-05-04 | Downgrade | Piper Sandler | Neutral → Underweight |
| 2022-04-05 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-03-25 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2022-01-27 | Downgrade | Argus | Buy → Hold |
| 2021-10-28 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-05-04 | Downgrade | UBS | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2020-11-25 | Iniziato | Oppenheimer | Perform |
| 2020-08-06 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2020-07-27 | Ripresa | Goldman | Neutral |
| 2020-06-01 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-04-24 | Ripresa | Citigroup | Neutral |
| 2020-04-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-02-24 | Downgrade | Edward Jones | Hold → Sell |
| 2019-11-12 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-10-17 | Aggiornamento | Gabelli & Co | Hold → Buy |
| 2019-08-07 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-07-19 | Iniziato | Wolfe Research | Peer Perform |
| 2019-07-15 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-07-10 | Ripresa | Credit Suisse | Neutral |
| 2019-07-05 | Aggiornamento | Argus | Hold → Buy |
| 2019-06-11 | Iniziato | Barclays | Underweight |
| 2019-06-03 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-05-30 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2019-05-28 | Downgrade | UBS | Buy → Neutral |
| 2019-03-20 | Iniziato | SunTrust | Hold |
| 2019-03-07 | Ripresa | UBS | Buy |
Mostra tutto
Teva Pharmaceutical Industries Ltd Adr Borsa (TEVA) Ultime notizie
Roundup: Teva Acquires BXCL501 for $57.5 Million Upfront, Rumi Therapeutics Enters Option Agreement for Fragile X PDE2 Inhibitor From Enthorin - Pharmaceutical Executive
Fourteen brokerages set USD 46.08 target for Teva stock - ad-hoc-news.de
Teva Pharmaceutical Industries (TEVA) Expected to Release Quarterly Earnings on Tuesday - MarketBeat
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline - GlobeNewswire
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline - Stock Titan
Teva reports 44-week duvakitug data for Teva stock - ad-hoc-news.de
Teva's Austedo-Led Turnaround Faces A Margin Test As Generics Drag On Third-Quarter Results - Finviz
Zacks downgrades Teva stock to Strong Sell below yearly high - ad-hoc-news.de
Is Teva Pharmaceutical Industries (TEVA) Still Undervalued Following Its Recent Pullback? - Simply Wall Street
Piper Sandler sets USD 44.00 target for Teva stock ahead of results - ad-hoc-news.de
Baron Health Care Fund Q3 2026 Top Contributors And Detractors - Seeking Alpha
Where Will Neurocrine Biosciences Be in 5 Years? - The Motley Fool
Teva Pharmaceutical Industries (TEVA) Stock Forecasts - Yahoo Finance
Teva stock: At 4.31 percent below its high, Teva stock traded at USD 40.21 on October 22 - ad-hoc-news.de
Teva reports Uvakitug efficacy data. November 3 results matter for Teva stock - ad-hoc-news.de
Teva reports 44-week data: What it means for Teva Pharmaceutical Industries stock - AD HOC NEWS
Teva (TEVA) Stock Looks Cheap Even After A 378% Run - Simply Wall Street
Sanofi & Teva’s IBD drug prompts long-term clinical remission in Phase IIb trial - Clinical Trials Arena
Active Pharmaceutical Ingredients Market Report Evaluates Growth Drivers, Challenges And Market Dynamics - openPR.com
Sanofi & Teva’s IBD drug prompts long-term clinical remission in Phase IIb trial - Yahoo Finance
Tetracyclines Market Research Reveals Strong 3.2% CAGR Outlook Through 2030 - openPR.com
Teva reports 44-week duvakitug data and Barclays targets Teva stock at USD 47.00 - AD HOC NEWS
Albuterol Market Report Provides Insights Into Market Evolution And Growth Prospects - openPR.com
Teva Pharmaceutical Industries Limited (TEVA) Latest Press Releases & Corporate News - Yahoo Finance
UEG Week: Teva and Sanofi's Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn's Disease - Investing News Network
UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term - GlobeNewswire
Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight - GlobeNewswire Inc.
Teva stock: At USD 41.29, Teva stock sits 1.74 percent below its 52-week high - ad-hoc-news.de
Teva Pharmaceutical Industries (TEVA) Gets FDA Nod For Monthly Schizophrenia Injection - Simply Wall Street
Stryker, Viatris, Flo, Teva, J&J: This Week in Healthcare - Healthcare Digital
Inside Teva's Weltruza launch and Novo's GLP-1 strategy - Fierce Pharma
Global Brain Health Supplements Market Size, Share, Trends and Forecast, 2026-2035 | Market to Reach USD 35.41 Billion as Natural Products and E-commerce Drive 11% CAGR - GlobeNewswire Inc.
Mayne Settles US Patent Suit With Teva Over Generic Imvexxy - Law360
Mayne Pharma clears another legal hurdle as Teva agrees to 2032 generic entry for Imvexxy - Business News Australia
Teva Pharmaceutical Industries (NYSE:TEVA) Given New $47.00 Price Target at Barclays - MarketBeat
Cash per share of Teva Pharmaceutical Industries Limited – BIVA:TEVA1/N - TradingView
Corcept Looks To End Teva's Mifepristone Antitrust Case - Law360
Small Molecule Active Pharmaceutical Ingredient Market Insights: Demand Trends, Competitive Landscape & Industry Outlook - EIN News
J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down - Zacks Investment Research
ETFs Investing in Teva Pharmaceutical Industries Limited Stocks - TradingView
Teva Pharmaceutical Industries Ltd. to Host R&D Day on November 11, 2026 - Quiver Quantitative
Teva to Host R&D Day on Wednesday, November 11 in New York City - GlobeNewswire Inc.
Teva to Host R&D Day on Wednesday, November 11 in New York City - GlobeNewswire
Teva to Host R&D Day on Wednesday, November 11 in New York City - GlobeNewswire
Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price Target Raised at JPMorgan Chase & Co. - MarketBeat
TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia - Zacks Investment Research
Teva Wins FDA Approval For Schizophrenia Innovation - Healthcare Digital
Teva Pharmaceutical Industries (TEVA): Transitioning from Generics to High-Margin Branded Drugs - Yahoo Finance
ETFs Investing in Teva Pharmaceutical Industries Limited Stocks - TradingView
Pretax income of Teva Pharmaceutical Industries Limited – BMV:TEVA1/N - TradingView
Teva Pharmaceutical Industries Ltd Adr Azioni (TEVA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Teva Pharmaceutical Industries Ltd Adr Azioni (TEVA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| MIGNONE ROBERTO | Director |
Sep 18 '26 |
Sale |
39.06 |
367,600 |
14,356,802 |
0 |
| Bridger Management, LLC (1) | Shareholder |
Sep 18 '26 |
Proposed Sale |
39.19 |
367,600 |
14,406,244 |
0 |
| Savage Brian | Officer |
Sep 18 '26 |
Proposed Sale |
38.85 |
7,028 |
273,062 |
0 |
| Savage Brian | Interim Chief Legal Officer |
Sep 18 '26 |
Sale |
38.85 |
7,342 |
285,215 |
8,500 |
| Satchi-Fainaro Ronit | Director |
Aug 21 '26 |
Sale |
37.25 |
415 |
15,459 |
111,986 |
| Weiss Amir | Chief Accounting Officer |
Aug 21 '26 |
Option Exercise |
19.61 |
2,500 |
49,025 |
15,571 |
| Weiss Amir | Chief Accounting Officer |
Aug 21 '26 |
Sale |
37.62 |
9,445 |
355,301 |
13,071 |
| Lippman Evan | EVP, Business Development |
Aug 17 '26 |
Sale |
36.57 |
18,600 |
680,291 |
25,591 |
| Lippman Evan | Officer |
Aug 17 '26 |
Proposed Sale |
36.57 |
18,600 |
680,291 |
0 |
| Zaks Tal Zvi | Director |
Aug 05 '26 |
Sale |
34.87 |
17 |
593 |
73,247 |
0.79%
0.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):